SCHEMBL2432429

SCHEMBL2432429

CC(=O)c1ccc(-c2nc3cc(Br)ccc3[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.61
MMP9 P14780 7/20 0.61
MMP8 P22894 7/20 0.61
MMP13 P45452 7/20 0.61
HDAC6 Q9UBN7 5/20 0.55
NPBWR1 P48145 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.53
CHEK2 O96017 2/20 0.50
RHEB Q15382 1/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
PKM P14618 1/20 0.48
NFKB1 P19838 1/20 0.48
RAB9A P51151 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450741 0.88 NPBWR1 (0.60) MMP2MMP9MMP8MMP13HDAC6
SCHEMBL6264473 0.86 CHEK2 (0.62) MMP2MMP9MMP8MMP13HDAC6
SCHEMBL25276426 0.83 KDM4E (0.62) MMP2MMP9MMP8MMP13KDM4E
SCHEMBL2649652 0.83 HDAC6 (0.61) MMP2MMP9MMP8MMP13HDAC6
SCHEMBL30563488 0.83 KDM4E (0.62) MMP2MMP9MMP8MMP13KDM4E
SCHEMBL15245067 0.82 CHEK2 (0.59) NPBWR1SIRT2CHEK2RHEBKDM4E
SCHEMBL2339150 0.82 MMP2 (0.71) MMP2MMP9MMP8MMP13HDAC6
SCHEMBL15223747 0.82 NPBWR1 (0.53) MMP2MMP9MMP8MMP13NPBWR1
SCHEMBL27236921 0.81 MMP2 (0.55) MMP2MMP9MMP8MMP13HDAC6
SCHEMBL15223798 0.81 CHEK2 (0.54) MMP2MMP9MMP8MMP13NPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 MMP2 3394/4885MMP9 3158/4885MMP8 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.